2020
2019
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
- Academic neurosurgery in the UK: present and future directions
- The effect of sleep deprivation and exercise on reaction threshold in peanut-allergic adults: a randomised controlled study
- Hyperphosphataemia in 2019: have we made progress?
- A randomised, double-blind, placebo-controlled crossover trial of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model: an enriched population trial
- Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)
- A zero coronary artery calcium score in patients with stable chest pain is associated with a good prognosis, despite risk of non-calcified plaques
- Keratinocyte growth factor impairs human thymic recovery from lymphopenia
- Dex-CSDH randomised, placebo-controlled trial of dexamethasone for chronic subdural haematoma: report of the internal pilot phase
- Vitamin D and Atherosclerotic Cardiovascular Disease
- Correction to: Dexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) trial: study protocol for a randomised controlled trial
- Non-invasive measurements of arterial function: What? When? Why should we use them?
- Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial
- Elucidating fitness components of the invasive dermestid beetle Trogoderma granarium combining deterministic and stochastic demography
- Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
- Influence of Antiplatelet and Anticoagulant Drug Use on Outcomes after Chronic Subdural Hematoma Drainage
- No Surgical Innovation Without Evaluation: Evolution and Further Development of the IDEAL Framework and Recommendations
- How to design a dose-finding study using the continual reassessment method
2018
- Randomised controlled trial of high versus ad libitum waterintake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial
- Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY - 2 mechanisms substudies
- Quality of stepped-wedge trial reporting can be reliably assessed using an updated CONSORT: crowd-sourcing systematic review
- PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial
- Dexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) trial: study protocol for a randomised controlled trial
- The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes
- Pharmacological management of post-traumatic seizures in adults: current practice patterns in the UK and the Republic of Ireland
- Targeting glucose control in preterm infants: pilot studies of continuous glucose monitoring
- Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial
- Theory of general balance applied to step wedge designs
- Does Drain Position and Duration Influence Outcomes in Patients Undergoing Burr-Hole Evacuation of Chronic Subdural Hematoma? Lessons from a UK Multicenter Prospective Cohort Study
- A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trial
- Protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care 'REACT'
- Vascular inflammation and aortic stiffness: potential mechanisms of increased vascular risk in chronic obstructive pulmonary disease
- Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial
- Identifying risk factors for L'Hermitte's sign after IMRT for head and neck cancer
- Outcomes following surgery in subgroups of comatose and very elderly patients with chronic subdural hematoma
- Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study
- The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial
- ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes
- PRedicting Outcomes For Crohn’s dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial
- The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
2017
- Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments.
- Survival Trends After Surgery for Acute Subdural Hematoma in Adults Over a 20-year Period.
- Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies.
- Quantitative analysis of dynamic 18F-FDG PET/CT for measurement of lung inflammation.
- Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies
- Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.
- Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
- Longitudinal follow-up of quadriceps strength and function in a COPD cohort after 3 years.
- Applying physical science techniques and CERN technology to an unsolved problem in radiation treatment for cancer: the multidisciplinary ‘VoxTox’ research programme.
2016
- Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
- Core Outcomes and Common Data Elements in Chronic Subdural Hematoma: A Systematic Review of the Literature Focusing on Baseline and Peri-Operative Care Data Elements.
- Surgical trainee research collaboratives in the UK: an observational study of research activity and publication productivity.
- Trastuzumab-associated cardiac events in the Persephone trial.
- Accumulated Dose to the Rectum, Calculated from Auto-contoured Image Guidance CT Scans, is Lower than Planned Dose in the Majority of Patients Treated with Radiotherapy for Prostate Cancer
- Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.
- Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
- The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case- Control Study.
- Tetrahydrobiopterin Supplementation Improves Endothelial Function But Does Not Alter Aortic Stiffness in Patients With Rheumatoid Arthritis.
- Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor.
- Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin- 2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
- The Cambridge Breast Intensity-modulated Radiotherapy Trial: Comparison of Clinician versus Patient-reported Outcomes
2015
- Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
- A Comparison of Outcomes Following Laparoscopic and Open Hysterectomy With or Without Lymphadenectomy for Presumed Early-Stage Endometrial Cancer: Results From the Medical Research Council ASTEC Trial
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
- A Bayesian adaptive design for biomarker trials with linked treatments.
- Neoadjuvant Trials in Early Breast Cancer: Pathological Response at Surgery and Correlation to Longer Term Outcomes – What does it all mean?
- A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
- Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
- Protocol of the adaptive study of IL-2 dose frequency in regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non randomised, repeat dose, open label, response adaptive study.
- Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
- Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
- Bevacizumab: the phoenix of breast oncology?
- The power of phase II end-points for different possible mechanisms of action of an experimental treatment.
- Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma.
- Surgeon-specific mortality data disguise wider failings in delivery of safe surgical services.
2014
- Ritiximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
- Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
- Study of induction of Tolerance to Oral Peanut: a randomised controlled trial of desensitisation using peanut oral immunotherapy in children (STOP II).
- Twist-drill craniostomy with hollow screws for evacuation of chronic subdural hematoma.
- Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial.
- Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
- Optimal treatment of early-stage ovarian cancer.
- Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial.
- Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease.
- Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.
- Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: results from the Cambridge Breast IMRT trial.
- Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
- Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
- Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.
- The Cambridge post-mastectomy radiotherapy (C-PMRT) index: a practical tool for patient selection.
- Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
- Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: rationale and design of the EARNEST study.
- Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
- Pre-dialysis systolic blood pressure-variability is independently associated with all-cause mortality in incident haemodialysis patients.
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
2013
- Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.
- Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
- A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial
- Is community treatment best? a randomised trial comparing delivery of cancer treatment in the hospital, home and GP surgery.
- ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study.
- Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009-2010).
- Stepped wedge cluster randomized trials are efficient and provide a method of evaluation without which some interventions would not be evaluated
2012
- Low absolute bioavailability of oral naloxone in healthy subjects.
- A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
- Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.
